Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Oral isotretinoin is the most effective choice in the treatment of severe acne. Application of isotretionin to acne has been expanded to treat those patients with less severe but scarring acne who are responding unsatisfactorily to conventional therapies. However, its use is associated with many side effects, some of which can result in very disastrous consequences. Data related with intermittent isotretinoin therapy is still limited. Our aim was to asses the efficacy and tolerability of two different intermittent isotretinoin courses and compare them with conventional isotretinoin treatment. In this multicenter and controlled study, 66 patients with moderate to severe cases were randomized to receive either isotretionin for the first 10 days of each month for 6 months (group 1), or each day in the first month, afterwards the first 10 days of each month for 5 months (group 2) or daily for 6 months (group 3). The drug dosage was 0.5 mg/kg/day in all groups. Patients were followed-up for 12 months. Efficacy values were evaluable for 22 patients in group 1, 19 patients in group 2, and 19 patients in group 3. Acne scores in each group were significantly lower at the end of treatment and follow-up periods (P < 0.001). When patients were evaluated separately as moderate (n = 31) and severe (n = 29), no statistically significant differences were obtained among the treatment protocols in patients with moderate acne. However, there was a significant difference between groups 1 and 3 to the response of the treatments in severe acne patients at the end of follow-up period (P = 0.013). The frequency and severity of isotretionin-related side effects were found to be lower in groups 1 and 2 compared with group 3. Intermittent isotretinoin may represent an effective alternative treatment, especially in moderate acne with a low incidence and severity of side effects. The intermittent isotretinoin can be recommended in those patients not tolerating the classical dosage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low-dose isotretinoin in the treatment of acne vulgaris
Amichai, B., Shemer, A., & Grunwald, M. H. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1061 · Cited by 177
Research works printed but not linked: 10
- Amichai B (2003) Long-term minidoses of isotretinoin in the treatment of relapsing acne. J Dermatol 30:572 · doi:10.1111/j.1346-8138.2003.tb00437.x
- Cunliffe WJ, Meynadier J, Alirezai M et al (2003) Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 49:218–226 · DOI
- Gollnick HP, Graupe K, Zaumseil RP (2001) Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 11:538–544
- Goulden V, Clark SM, Mcgeown C, Cunliffe WJ (1997) Treatment of acne with intermittent isotretinoin. Br J Dermatol 137:106–108 · DOI · Paper page
- Kaymak Y, İlter N (2006) The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol 20:1256–1260 · DOI · Paper page
- Layton AM, Dreno B, Gollnick HP, Zouboulis CC (2006) A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 20:773–776 · DOI · Paper page
- Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G (2003) Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 23:41–46
- Palmer RA, Sidhu S, Goodwin PG (2000) ‘Microdose’ isotretinoin. Br J Dermatol 143:205–206 · DOI
- Seukeran DC, Cunliffe WJ (1998) Acne vulgaris in the elderly; the response to low-dose isotretinoin. Br J Dermatol 139:99–101 · DOI
- Struss JS, Leyden JJ, Lucky AW et al (2001) Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 45:196–207 · DOI
Cited by
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
European Evidence‐based (S3) Guidelines for the Treatment of Acne
Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López‐Estebaranz, J. L., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04374.x · Cited by 426
Lee, J. W., Yoo, K. H., Park, K. Y., Han, T. Y., Li, K., Seo, S. J., & Hong, C. K. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10152.x · Cited by 127
Bagatin, E., Guadanhim, L. R. S., Enokihara, M. M. S. S., Sanudo, A., Talarico, S., Miot, H. A., & Gibson, L. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12191 · Cited by 52
Oral isotretinoin for acne: a complete overview
Villani, A., Nastro, F., Di Vico, F., Fabbrocini, G., Annunziata, M. C., & Genco, L. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2102605 · Cited by 42
“Akman et al. [30] enrolled 66 patients with moderate-tosevere acne, randomly sorted into 3 groups given isotretinoin as follows: (A) 0.5 mg/kg/day for 6 months, (B) 0.5 mg/kg/day for 10 days per month for 6 months, and (C) 0.5 mg/kg/day for 1 month, followed by the same dosage for the first 10 days of each month for o…”
MethodInfluential
Metadata
- Authors
- Akman, A., Durusoy, C., Senturk, M., Koc, C. K., Soyturk, D., & Alpsoy, E.
- Venue
- Archives of Dermatological Research
- Published
- 2007-08-21
- Volume
- 299
- Issue
- 10
- Pages
- 467-473
- ISSN
- 0003-9187 (ISSN-L)
- 0340-3696
- 1432-069X
- OpenAlex
- W1983371617
- Cited by
- 92
- References
- 1
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc/2.0 (tdm)
- creativecommons.org/licenses/by-nc/2.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.